Table 2.
Correlation of CDCA3 mRNA expression and prognosis in hepatocellular carcinoma with different clinicopathologic features by the Kaplan–Meier plotter.
| Clinicopathologic features | Overall survival | Progression-free survival | ||||
|---|---|---|---|---|---|---|
| N | Hazard ratio | p value | N | Hazard ratio | p value | |
| Sex | ||||||
| Female | 118 | 2.17 (1.24-3.81) | 0.0058 | 121 | 2.19 (1.25-3.84) | 0.0052 |
| Male | 246 | 1.81 (1.15-2.84) | 0.0095 | 249 | 1.76 (1.21-2.54) | 0.0024 |
| Stage | ||||||
| I | 170 | 1.95 (0.97-3.89) | 0.055 | 171 | 1.64 (1-2.71) | 0.049 |
| II | 83 | 4.39 (1.5-12.83) | 0.0031 | 84 | 1.76 (0.92-3.37) | 0.082 |
| I+II | 253 | 2.33 (1.32-4.11) | 0.0026 | 254 | 1.52 (1.04-2.23) | 0.029 |
| II+III | 166 | 2.56 (1.51-4.34) | 0.00031 | 167 | 1.95 (1.23-3.1) | 0.0041 |
| III | 83 | 2.32 (1.27-4.22) | 0.0047 | 83 | 2.05 (1.09-3.86) | 0.022 |
| III+IV | 87 | 2.18 (1.22-3.9) | 0.0074 | 88 | 2.18 5(1.17-4.08) | 0.012 |
| V | 4 | — | — | 5 | — | — |
| Grade | ||||||
| 1 | 55 | 4.97 (1.73-14.25) | 0.0013 | 55 | 2.8 (1.16-6.79) | 0.019 |
| 2 | 174 | 1.97 (1.13-3.44) | 0.015 | 175 | 2.15 (1.39-3.34) | 0.00044 |
| 3 | 118 | 2.22 (1.21-4.09) | 0.0085 | 119 | 1.67 (0.99-2.83) | 0.051 |
| 4 | 12 | — | — | 12 | — | — |
| AJCC_T | ||||||
| 1 | 180 | 1.87 (0.98-3.56) | 0.055 | 180 | 1.63 (1-2.65) | 0.047 |
| 2 | 90 | 3.69 (1.4-9.7) | 0.0047 | 92 | 1.99 (1.07-3.69) | 0.026 |
| 3 | 78 | 2.31 (1.25-4.25) | 0.0059 | 78 | 2.25 (1.08-4.68) | 0.026 |
| 4 | 13 | — | — | 13 | — | — |
| Vascular invasion | ||||||
| None | 203 | 2.09 (1.14-3.81) | 0.015 | 204 | 1.47 (0.94-2.3) | 0.089 |
| Micro | 90 | 2.15 (0.86-5.35) | 0.092 | 91 | 1.57 (0.85-2.9) | 0.14 |
| Macro | 16 | — | — | 16 | — | — |
| Race | ||||||
| White | 181 | 2.48 (1.27-4.84) | 0.0059 | 183 | 2.02 (1.29-3.14) | 0.0016 |
| Black or African man | 17 | — | — | 17 | — | — |
| Asian | 155 | 3.01 (1.57-5.76) | 0.00048 | 155 | 1.91 (1.18-3.08) | 0.007 |
| Alcohol consumption | ||||||
| Yes | 115 | 1.41 (0.75-2.67) | 0.29 | 115 | 1.97 (1.17-3.34) | 0.0099 |
| None | 202 | 1.63 (1.03-2.59) | 0.037 | 204 | 1.47 (0.98-2.19) | 0.06 |
| Virus hepatitis | ||||||
| Yes | 150 | 1.19 (0.62-2.27) | 0.6 | 152 | 0.96 (0.61-1.52) | 0.86 |
| None | 167 | 2.18 (1.37-3.45) | 0.00073 | 167 | 2.67 (1.69-4.21) | 1.1e − 05 |
Note: N represents the numbers of patients with different clinicopathologic features; the hazard ratio represents the higher risk factors produced by high CDCA3 expression affected in the prognosis of patients with different clinicopathologic features; clinicopathologic features include stage, grade, AJCC_T, vascular invasion, gender, race, sorafenib treatment, alcohol consumption, and hepatitis virus; bold values indicate p < 0.05; p < 0.05 was statistically significant.